Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic
dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell
(SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular
therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological
agent available to limit AAA expansion. In the past decades, extensive investigations and a body of
ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.
Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides,
tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid,
anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular
targets, which have potential to be translated into clinical practice in the future.